Cubist is ditching 177 Optimer jobs after its $535M buyout

Just over a month after crossing the T's on a $535 million acquisition by Cubist Pharmaceuticals ($CBST), Optimer Pharmaceuticals is shedding 177 jobs in the U.S. and Canada, New Jersey's Star-Ledger reports. Massachusetts-based Cubist is shutting down Optimer's Garden State headquarters next year, according to the newspaper, and the company is working with affected employees to see if they might fit in elsewhere in its operations. Report

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.